Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Massachusetts amends anti-kickback law to permit certain prescription drug coupons

By Isabel Dunst, Sara A. Kraner & Andrew Furlow on July 12, 2012
Email this postTweet this postLike this postShare this post on LinkedIn

Massachusetts has amended its anti-kickback law to permit manufacturers to provide certain prescription drug coupons.  The state’s anti-kickback statute contains a broad prohibition that formerly precluded manufacturers from providing any type of cost reduction to privately-insured state residents.  As of this week, however, it contains an exception that allows manufacturers to provide discounts, rebates, product vouchers, or other reductions in an individual’s out-of-pocket expenses (including copayment and deductibles) on a biological or prescription drug, so long as that cost reduction is provided directly or electronically to the individual or through a point of sale or mail-in rebate, or through similar means.

The new exception is subject to restrictions.  Manufacturers may not exclude or favor any pharmacy in the redemption of the discount, rebate, voucher, or other reduction of out-of-pocket expenses, and manufacturers may not offer such an expense reduction for any prescription drug that has an AB-rated generic equivalent. 

The law also permits retail pharmacies to provide discounts or free product vouchers to consumers in connection with a pharmacy service, item, or prescription transfer offer. 

These amendments represent a significant change for the manufacturers doing business in Massachusetts.  Manufacturers may now provide privately-insured state residents with coupons, co-pay cards, vouchers, and other cost-sharing reductions for their prescription drugs and biologicals so long as the statutory restrictions are followed.  Of course, the federal anti-kickback law prohibitions still apply to Massachusetts residents enrolled in Medicare, Medicaid, and other federal health care programs.

For more information, please reference our client alert.

  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo